Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy

References

• Ando H, Kobayashi S, Abu Lila AS, et al. (2015). Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed. J Control Release 220:29–36.
   PubMed Web of Science ®Google Scholar
• Anitha A, Sowmya S, Kumar PTS, et al. (2014). Chitin and chitosan in selected biomedical applications. Prog Polym Sci 39:1644–67.
   Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. (2012). Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev 64:206–12.
   Web of Science ®Google Scholar
• Canal F, Vicent MJ, Pasut G, et al. (2010). Relevance of folic acid/polymer ratio in targeted PEG–epirubicin conjugates. J Control Release 146:388–99.
   PubMed Web of Science ®Google Scholar
• Chan M, Gravel M, Bramoulle A, et al. (2014). Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption. Cancer Res 74:5948–54.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Moran RG, Goldman ID. (2007). Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404–17.
   PubMed Web of Science ®Google Scholar
• Chen J, Huang LQ, Lai HX, et al. (2014). Methotrexate-loaded PEGylated chitosan nanoparticles: synthesis, characterization, and in vitro and in vivo antitumoral activity. Mol Pharmaceutics 11:2213–23.
   PubMed Web of Science ®Google Scholar
• Chen MC, Mi FL, Liao ZX, et al. (2013). Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev 65:865–79.
   PubMed Web of Science ®Google Scholar
• Cheng R, Meng FH, Deng C, et al. (2013). Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 34:3647–57.
   PubMed Web of Science ®Google Scholar
• Chou TC. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621–81.
   PubMed Web of Science ®Google Scholar
• Chou TC. (2010). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–6.
   PubMed Web of Science ®Google Scholar
• Decuzzi P, Godin B, Tanaka T, et al. (2010). Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release 141:320–7.
   PubMed Web of Science ®Google Scholar
• El-Say KM, El-Sawy HS. (2017). Polymeric nanoparticles: promising platform for drug delivery. Int J Pharm 528:675–91.
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. (2011). The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136–51.
   PubMed Web of Science ®Google Scholar
• Farjadian F, Ghasemi S, Mohammadi-Samani S. (2016). Hydroxyl-modified magnetite nanoparticles as novel carrier for delivery of methotrexate. Int J Pharm 504:110–6.
   PubMed Web of Science ®Google Scholar
• Guo YX, Zhang Y, Ma JY, et al. (2018). Light/magnetic hyperthermia triggered drug released from multi-functional thermo-sensitive magnetoliposomes for precise cancer synergetic theranostics. J Control Release 272:145–58.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144:646–74.
   PubMed Web of Science ®Google Scholar
• He CB, Lu JQ, Lin WB. (2015). Hybrid nanoparticles for combination therapy of cancer. J Control Release 219:224–36.
   PubMed Web of Science ®Google Scholar
• Hu QY, Sun WJ, Wang C, et al. (2016). Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev 98:19–34.
   PubMed Web of Science ®Google Scholar
• Jain A, Jain A, Garg NK, et al. (2015). Surface engineered polymeric nanocarriers mediate the delivery of transferrin-methotrexate conjugates for an improved understanding of brain cancer. Acta Biomater 24:140–51.
   PubMed Web of Science ®Google Scholar
• Jenkins SI, Pickard MR, Furness DN, et al. (2013). Differences in magnetic particle uptake by CNS neuroglial subclasses: implications for neural tissue engineering. Nanomedicine 8:951–68.
   PubMed Web of Science ®Google Scholar
• Kemp JA, Shim MS, Heo CY, et al. (2016). “Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv Drug Delivery Rev 98:3–18.
   PubMed Web of Science ®Google Scholar
• Khan ZA, Tripathi R, Mishra B. (2012). Methotrexate: a detailed review on drug delivery and clinical aspects. Expert Opin Drug Deliv 9:151–69.
   PubMed Web of Science ®Google Scholar
• Kohay H, Sarisozen C, Sawant R, et al. (2017). PEG-PE/clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity. Acta Biomater 55:443–54.
   PubMed Web of Science ®Google Scholar
• Li WJ, Zhan P, De Clercq E, et al. (2013). Current drug research on PEGylation with small molecular agents. Prog Polym Sci 38:421–44.
   Web of Science ®Google Scholar
• Li Y, Lin JJ, Ma JY, et al. (2017a). Methotrexate-camptothecin prodrug nanoassemblies as a versatile nanoplatform for biomodal imaging-guided self-active targeted and synergistic chemotherapy. Acs Appl Mater Interfaces 9:34650–65.
   PubMed Web of Science ®Google Scholar
• Li Y, Song L, Lin JY, et al. (2017b). Programmed nanococktail based on ph-responsive function switch for self-synergistic tumor-targeting therapy. Acs Appl Mater Interfaces 9:39127–42.
   PubMed Web of Science ®Google Scholar
• Liu GH, Ma JY, Li Y, et al. (2017). Core-interlayer-shell Fe3O4@mSiO(2)@lipid-PEG-methotrexate nanoparticle for multimodal imaging and multistage targeted chemo-photodynamic therapy. Int J Pharm 521:19–32.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yin Y, Wang LY, et al. (2013). Surface hydrophobicity of microparticles modulates adjuvanticity. J Mater Chem B 1:3888–96.
   PubMed Web of Science ®Google Scholar
• Lu NN, Li RT, Liu Q, et al. (2016). Antitumor and antimetastatic effects of pemetrexed-loaded targeted nanoparticles in B16 bearing mice. Drug Deliv 23:2566–74.
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. (2016). Cancer treatment and survivorship statistics, 2016. Ca-Cancer. CA Cancer J Clin 66:271–89.
   PubMed Web of Science ®Google Scholar
• Modaresifar K, Azizian S, Hadjizadeh A. (2016). Nano/biomimetic tissue adhesives development: from research to clinical application. Polym Rev 56:329–61.
   Web of Science ®Google Scholar
• Perry JL, Reuter KG, Luft JC, et al. (2017). Mediating passive tumor accumulation through particle size, tumor type, and location. Nano Lett 17:2879–86.
   PubMed Web of Science ®Google Scholar
• Ramirez M, Rajaram S, Steininger RJ, et al. (2016). Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Comms 7:10690.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2017). Cancer Statistics, 2017. Ca-Cancer. J Clin 67:7–30.
   Google Scholar
• Singh VK, Subudhi BB. (2016). Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery. Drug Deliv 23:2327–37.
   PubMed Web of Science ®Google Scholar
• Srinivas NSK, Verma R, Kulyadi GP, et al. (2016). A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. IJN 12:15–28.
   Web of Science ®Google Scholar
• Tan WL, Jain A, Takano A, et al. (2016). Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol 17:e347–E62.
   PubMed Web of Science ®Google Scholar
• Wang X, Tang H, Wang CZ, et al. (2016). Phenylboronic acid-mediated tumor targeting of chitosan nanoparticles. Theranostics 6:1378–92.
   PubMed Web of Science ®Google Scholar
• Wang YW, Zhang HY, Hao J, et al. (2015). Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug Deliv 23, 1398–403.
   Google Scholar
• Weeks JC, Catalano PJ, Cronin A, et al. (2012). Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367:1616–25.
   PubMed Web of Science ®Google Scholar
• Wibowo AS, Singh M, Reeder KM, et al. (2013). Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proc Natl Acad Sci USA 110:15180–8.
   PubMed Web of Science ®Google Scholar
• Win KY, Feng SS. (2005). Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:2713–22.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Zhao Y, Miao L, et al. (2016). Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J Control Release 244:63–73.
   PubMed Web of Science ®Google Scholar
• Xu YR, Asghar S, Yang L, et al. (2017). Nanoparticles based on chitosan hydrochloride/hyaluronic acid/PEG containing curcumin: In vitro evaluation and pharmacokinetics in rats. Int J Biol Macromol 102:1083–91.
   PubMed Web of Science ®Google Scholar
• Yamashita F, Hashida M. (2013). Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev 65:139–47.
   PubMed Web of Science ®Google Scholar
• Yan JK, Wang YZ, Zhang XF, et al. (2016). Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Deliv 23:1757–62.
   PubMed Web of Science ®Google Scholar